<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/23AF224A-F5E4-473B-81FF-CB1A61C8F860"><gtr:id>23AF224A-F5E4-473B-81FF-CB1A61C8F860</gtr:id><gtr:name>Vertellus</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/91427003-DFB6-48F9-848A-32A456E1C00F"><gtr:id>91427003-DFB6-48F9-848A-32A456E1C00F</gtr:id><gtr:name>Royal Free Hospital</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Institute of Ophthalmology</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/23AF224A-F5E4-473B-81FF-CB1A61C8F860"><gtr:id>23AF224A-F5E4-473B-81FF-CB1A61C8F860</gtr:id><gtr:name>Vertellus</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/91427003-DFB6-48F9-848A-32A456E1C00F"><gtr:id>91427003-DFB6-48F9-848A-32A456E1C00F</gtr:id><gtr:name>Royal Free Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/0773867B-E6D7-4977-9933-C44BEE027C00"><gtr:id>0773867B-E6D7-4977-9933-C44BEE027C00</gtr:id><gtr:firstName>Stephen</gtr:firstName><gtr:otherNames>James</gtr:otherNames><gtr:surname>Brocchini</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B8B460BB-2C6E-41DD-B963-764DFE9F5171"><gtr:id>B8B460BB-2C6E-41DD-B963-764DFE9F5171</gtr:id><gtr:firstName>Peng Tee</gtr:firstName><gtr:surname>Khaw</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0801650"><gtr:id>84A8FA87-9078-4C8F-B5B6-BE7F04D32DAD</gtr:id><gtr:title>Novel tissue implantable slow release tablet therapy to prevent scarring</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0801650</gtr:grantReference><gtr:abstractText>There are no licensed treatments to prevent scarring in the human body. Scarring plays a part in most of the major blinding conditions in the world today. It is also important in many lung, heart, kidney, intestinal, brain and skin conditions.

The group of eye diseases called glaucoma are the commonest cause of irreversible blindness worldwide and the commonest reason for an eye outpatient appointment. In glaucoma the nerve carrying vision to the brain gradually collapses. We treat glaucoma by lowering the eye pressure. We can create a new eye drainage channel. Unfortunately this fails due to scarring. In our recent long term surgery study, in patients who had minimal scarring with low pressures not one patient got worse over nearly a decade. In contrast if scarring was bad 24% got worse. The problem is we can only achieve this in 30% of people using an anticancer agent called 5-fluorouracil.

We have discovered that inhibiting enzymes called matrix metalloproteinases dramatically reduces scarring. When we inject this after glaucoma surgery we greatly reduce scarring, more than any anticancer agent we currently use. The problem is we have to inject the eye many times. We have now invented a way to make it into a tiny tablet which is painlessly placed into the operation area. This releases the drug at just the right level. A pilot study has shown this tablet is better than anything we currently have. The aim of this project is to scientifically develop the best shape and concentration of the tablet and then scale this up for human use and benefit.

This is being carried out by research groups at UCL Ophthalmology and the London School of Pharmacy, two groups with a world-class track record for developing new treatments. They are part of the new National Institute for Health Research Biomedical Research Centre which has been established to ?fast track? developments like this rapidly though to patient benefit and include the new NHS Pharmaceutical production facility at Moorfields Eye Hospital.

If successful, this new single tablet has the potential to considerably improve the treatment of glaucoma all over the world with fewer visits to clinic and prevention of blindness. There is great potential to improve the treatment of other diseases of the eye including macular degeneration, diabetic retinopathy, retinal detachment, blinding retinopathy of premature children and other scarring problems in the human body.</gtr:abstractText><gtr:technicalSummary>The causes of fibrosis are complex and contribute to many human diseases, including every major blinding disease. There is a large unmet need for anti-scarring therapies; with at least 42 million procedures in 2004 which could have benefited from anti-scarring products. Administration of cytotoxic agents directly into the eye after surgery to control fibrosis to manage healing is currently the best clinical treatment available. There are many side effects because repeat injections of high doses that rapidly clear are toxic locally and systemically. There is a need to control fibrosis both generally and in the eye after surgery as there are no licensed treatments. 
 
We have solved two major problems of current anti-fibrotic treatments: (1) To address toxicity, we have discovered that repeat injections of a metalloprotease (MMP) inhibitor have a markedly beneficial effect on scarring reduction without the toxicity of cytotoxic agents. (2) To address tissue specific pharmacokinetics, we developed a novel, small, resorbable tissue-tablet to release the MMP inhibitor locally at the fibrotic site. Using a clinically validated in vivo model, prolonged release profiles are achieved with a 100% surgical success rate to date. Preliminary results support a clear pathway to develop the MMP tablet to treat post-surgical fibrosis.</gtr:technicalSummary><gtr:fund><gtr:end>2013-10-25</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-10-26</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>744263</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Vertellus</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Vertellus PC Biomaterials</gtr:description><gtr:id>C1FF50FD-F997-4AE2-BEB3-C2D9CB8FE148</gtr:id><gtr:impact>Successfully applied together for NIHR i4i Challenge Award for the development of a novel glaucoma device.</gtr:impact><gtr:outcomeId>548b2f804a5165.01454738-1</gtr:outcomeId><gtr:partnerContribution>Expertise and experience in pc polymers and biocompatible materials.</gtr:partnerContribution><gtr:piContribution>We work with Vertellus to develop biocompatible polymers and they are a co-applicant on our NIHR i4i Challenge award.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Free Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Biocompatible coating</gtr:description><gtr:id>452A4B9F-6CDD-4640-87FF-30ACC924A759</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>CcxGFvvn8KN-1</gtr:outcomeId><gtr:partnerContribution>Access to a biocompatible polymer</gtr:partnerContribution><gtr:piContribution>To better treat subconjunctival fibrosis after glaucoma filtration surgery we are examining how changes in surgery procedure and the therapeutic agents that are used are necessary. To aid development of new surgical devices that might be developed into combination devices that also deliver a drug, we have sought a biocompatible polymer.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Canadian Ophthalmology Society Invited Speaker</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>3A97558C-931F-4ABE-B5C7-54C8E0076849</gtr:id><gtr:impact>Gave 3 talks at the conference in Halifax, Canada: &amp;quot;Advances in the management of childhood glaucoma&amp;quot;, &amp;quot;Optimising glaucoma filtration surgery in children&amp;quot; and &amp;quot;Optimizing glaucoma filtration surgery&amp;quot;.

Dissemination of information amongst peers.</gtr:impact><gtr:outcomeId>53a93d61072a96.13585804</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.cos-sco.ca/cpd/education/annual-meeting/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>President, UK Paediatric Glaucoma Society</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>066E41CF-A0A9-4236-B94A-F3F08ACCDE44</gtr:id><gtr:impact>Talk and discussions with both national and international peers to discuss paediatric management of glaucoma.

Have been given the opportunity of hosting the meeting in the US so that more US colleagues can attend.</gtr:impact><gtr:outcomeId>53a82193e91067.91998208</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Glaucoma Patient Day</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3EEC2078-21C5-4F32-B9BE-CAB79963EA47</gtr:id><gtr:impact>Small break out groups led by researchers addressed questions and sought patients' views on what they felt was important to them in terms of the type of research being carried out to help combat eye disease.

Dissemination of information in relation to they type of research carried out. Exercise to establish what patients want.</gtr:impact><gtr:outcomeId>5453ab2ab19345.02180180</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>London Deanery School of Ophthalmology Conference (2012)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1233A142-F0F5-41F0-BA36-9516227B32E2</gtr:id><gtr:impact>Talk on 'Academic ophthalmology: A career choice'
21 March 2012
Holborn Bars

Talk to inspire the next generation to consider a career in research</gtr:impact><gtr:outcomeId>ZAjKRCx9Hcz</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Four Liveries' Lecture on behalf of the Spectacle Makers' Company</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>3530F14F-C39A-426A-9CEB-91AF6A89C9AB</gtr:id><gtr:impact>Talk on 'Stopping Scarring Saves Sight - How New Treatments to Prevent Scarring can Save and Restore Vision'

What glaucoma is, the problems faced and what we are doing to combat glaucoma with research and innovations.</gtr:impact><gtr:outcomeId>WAbDut6upp3</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>House of Lords Science &amp; Technology Committee (2012)</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B0C1B0E0-3ABD-424C-8878-AB600896823C</gtr:id><gtr:impact>Meeting transcribed and recorded to be available online on parliament.tv to be viewed by the public. Answered questions from the public.

Public made aware of the advancements and impact translational drug delivery.</gtr:impact><gtr:outcomeId>qxV9vmeqb51</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>RCOphth New Frontiers in Management of Glaucoma Seminar</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>97D298D3-3E2A-4F9E-B2A6-8CC3860EBFEB</gtr:id><gtr:impact>16 September 2013 at the Institute of Physics in London. Talk &amp;quot;Translating research into new glaucoma treatments&amp;quot;.

Dissemination of information particularly how research can help with new and fast tracked treatments for diseases and how important it is that research continues and translation from the lab to clinic is as fast as possible.</gtr:impact><gtr:outcomeId>53a44c53672d39.72544582</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>World Ophthalmological Congress</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D2C3E1E8-9604-4737-9C48-889A375B69B0</gtr:id><gtr:impact>100s of attendance. Held in Tokyo. 'Glaucoma: Repair and Regeneration from the Front to the Back of the Eye', 'Modulating Wound Healing'and &amp;quot;Prospects for Optic Nerve Repair and Regeneration&amp;quot;

Dissemination of information amongst peers. One of the talks was for the Royal College of Ophthalmology Symposium which showcased, UK research.</gtr:impact><gtr:outcomeId>53a93e87c2c078.75679494</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.woc2014.org/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>European Glaucoma Society Keynote Lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>18C2246F-2C19-47C3-9795-8D954A0E802F</gtr:id><gtr:impact>100s of attendees. Held in Nice in 2014. Also gave two other talks on &amp;quot;Maximising success and minimsing complications in paediatric GFS&amp;quot; and &amp;quot;A glance into the future: New delivery systems&amp;quot;

http://www.eugs.org/</gtr:impact><gtr:outcomeId>53a93cc8ab0654.82724208</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Royal College of Ophthalmologists Admissions Ceremony</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>21EB8CF1-7A6D-42A4-989D-AFCDC43A6F04</gtr:id><gtr:impact>To enthuse new members

Dissemination of information</gtr:impact><gtr:outcomeId>5453a85f9e45e8.42341672</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.rcophth.ac.uk/page.asp?section=601&amp;sectionTitle=Admission+Ceremony</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk to trainees &amp; consultants at the North Thames Regional Study Day</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>7ADA5F13-798A-4248-8F77-CA866A018FA4</gtr:id><gtr:impact>Talk on 'Meeting unmet needs in glaucoma - A future look' 
22 June 2012 
London School of Hygiene and Tropical Medicine

The importance of academic ophthalmology and future research.</gtr:impact><gtr:outcomeId>oB3tLf94qRf</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk to lay membership of Moorfields NHS Foundation Trust</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>A395F6F7-6254-4C26-98A3-6142530BF5E4</gtr:id><gtr:impact>Attended by several hindred members. Interest in the reseacrh expressed afterwards.

Incresed levels of awareness of research and new developments leading to improved clinical care and treatment.</gtr:impact><gtr:outcomeId>fP9KiCcu3CE</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation to the public for Glaucoma &amp; Me Day: Look to the Future.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>7ABC7F46-EEE7-4C0C-906D-35D31AF0EFA2</gtr:id><gtr:impact>Talk on 'Look to the future'
10 July 2012
Royal Society of Medicine


Great involvement with the public and dissemination of information on why research matters and the advances being made.</gtr:impact><gtr:outcomeId>Uz2LUmqWz9z</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Glaucoma Patient Day</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>CB89CB9A-A390-4034-B364-4ECAA010909F</gtr:id><gtr:impact>300 people attended

Dissemination of information on current research practices and innovations. Listening to what patients wanted and what was important to them.</gtr:impact><gtr:outcomeId>WBh6BqX4Gjb</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>RNIB Board of Trustees</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>7EF18CCB-0706-409A-A543-6F8E793C81D1</gtr:id><gtr:impact>Presentation to the Board of Trustees of the RNIB.
29 November 2012


To provide information on current research initiatives and projects to hopefully forge greater collaboration.</gtr:impact><gtr:outcomeId>UXYaL8fTZoS</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>SENSORY SYSTEMS: FORGING NEW PARTNERSHIPS BETWEEN ACADEMIA AND INDUSTRY</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>AF11ACA8-79D0-468E-BE8F-BE09AE850993</gtr:id><gtr:impact>11 November 2013 at the Institute of Physics, London. Participants included peers, colleagues and people from Industry with talks from scientists to showcase new and existing partnerships in industry and how we could all work to together even more to try and find cures.

Good networking opportunity with collaborators and industry to try and forge new links for working together on projects.</gtr:impact><gtr:outcomeId>53a450888aaec3.07206654</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Keynote Speaker, Academy of Medical Sciences Conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>93BA33B3-B159-475D-A7AF-EC087D4913E3</gtr:id><gtr:impact>Talk on 'Opportunities in Academic Medicine' 
27 November 2009
Victoria Park Plaza Hotel, London

Aimed at young doctors to enthuse them into research to consider a careers as a clinician scientist.</gtr:impact><gtr:outcomeId>WiQs859e58P</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Therapeutic Innovation Fund/UCL</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>University College London</gtr:fundingOrg><gtr:id>1EFDEE53-16F3-461D-A691-8AE110B39308</gtr:id><gtr:outcomeId>Svikhd9A29R0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1100</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>ARVO Travel Grant for Richard MH Lee</gtr:description><gtr:end>2016-05-02</gtr:end><gtr:fundingOrg>Association for Research in Vision and Ophthalmology (ARVO)</gtr:fundingOrg><gtr:id>DA1F0A7D-6262-4768-96EF-365E63D53347</gtr:id><gtr:outcomeId>58ca637ba7b0d9.92140376</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5168035</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EP/I033270/1 EPSRC centre for innovative manufacturing in emergent macromolecular therapies</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>EP/I033270/1</gtr:fundingRef><gtr:id>D5393F85-D792-4348-BB85-A92ADA2F16E6</gtr:id><gtr:outcomeId>MntxfvnZGmS0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Knowledge champions funding polymer drug delivery</gtr:description><gtr:end>2012-11-02</gtr:end><gtr:fundingOrg>UCL Business</gtr:fundingOrg><gtr:id>CF285549-4900-4BCD-B645-B8CC418F680D</gtr:id><gtr:outcomeId>qC15PNCEsrp0</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2011-12-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Healthcare and Life Sciences Global Business Summit</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>14A5BD96-B665-42D1-8D0A-8D9C1C32FDDC</gtr:id><gtr:outcomeId>GQHR14LmkUk</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Presentation to Earl Howe, Undersecretary of State for Health, NIHR</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>18182969-C9B8-49CD-9D41-0521992F9392</gtr:id><gtr:outcomeId>A1Rj1PagaNn</gtr:outcomeId><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>EU Vision Institute meeting for the European Parliament</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:id>DD85DA63-030D-4D83-88D9-50E75C14D080</gtr:id><gtr:outcomeId>mRZaYsRxXkP</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>House of Lords Science &amp;amp; Technology Committee on Regenerative Medicine (2012)</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F31AC336-33BE-4688-990D-EF9741EC4196</gtr:id><gtr:outcomeId>nh1QvwdtFnx</gtr:outcomeId><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>NEI Audacious Goals</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:id>7A2A7BD6-7D68-4D15-BBCA-C47D10C63C9D</gtr:id><gtr:outcomeId>nEHP5G6XNG4</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>2013 International Review Panel for the Centre for Eye Research Australia (CERA)</gtr:description><gtr:geographicReach>Australia</gtr:geographicReach><gtr:id>FD613388-6C4E-46AD-A0A2-E53F23722223</gtr:id><gtr:outcomeId>53a44f3a59dc67.78986238</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type><gtr:url>http://www.cera.org.au/</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>Currently being enhanced, supported by DPFS scheme and Therapeutic Innovation Fund</gtr:description><gtr:id>354F5E0E-618E-4F23-856B-37932A784666</gtr:id><gtr:impact>Not yet</gtr:impact><gtr:outcomeId>dRmxBMpkuW1</gtr:outcomeId><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Slow release anti-scarring tablet</gtr:title><gtr:type>Therapeutic Intervention - Surgery</gtr:type><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Rabbit model of glaucoma filtration surgery developed. Model used to study the modulation of scarring after glaucoma filtration surgery, as well as to test the biocompatibility of materials developed for glaucoma devices.</gtr:description><gtr:id>E3F9750B-CEF0-4E22-ACB5-01EE72F4945A</gtr:id><gtr:impact>Dialogue started with pharmaceutical companies</gtr:impact><gtr:outcomeId>FjNH5XizimR</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>In vivo model (rabbit) of slow release tablet for the modulation of scarring</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>244A0132-2D40-4A10-82A6-9C9DC5CF7B4E</gtr:id><gtr:title>Magnetic Resonance Imaging of the Rabbit Eye to Determine the Presence of Bevacizumab (Avastin) Tablet in the Posterior Sclera</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7f205256d58e116c0782f573209d784b"><gtr:id>7f205256d58e116c0782f573209d784b</gtr:id><gtr:otherNames>Khaw P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>mVHNo8QyrnV</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BF15FD0A-CA3E-4FC0-A8E4-36B9239BAFB9</gtr:id><gtr:title>The Effect Of Gamma Irradiation On The Physicochemical Properties Of A Matrix Metalloproteinase Inhibitor Ilomastat: A Multi-supplier Consistency Study</gtr:title><gtr:parentPublicationTitle>IOVS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d5ec7c39a6c847edf801731d4edd0c65"><gtr:id>d5ec7c39a6c847edf801731d4edd0c65</gtr:id><gtr:otherNames>Vetter A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>547de86d3d0678.21948815</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B19FF064-BDFD-49EB-ADB4-8755E23AB4DF</gtr:id><gtr:title>Advancing the treatment of conjunctival scarring: a novel ex vivo model.</gtr:title><gtr:parentPublicationTitle>Archives of ophthalmology (Chicago, Ill. : 1960)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b847abee8ff432e1aa86afb9f5a4dec5"><gtr:id>b847abee8ff432e1aa86afb9f5a4dec5</gtr:id><gtr:otherNames>Tovell VE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0003-9950</gtr:issn><gtr:outcomeId>doi_12768_ol_2011_91</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B2FAA02-BBC2-413D-9F28-8D2821191F41</gtr:id><gtr:title>Principles of pharmacology in the eye.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8ecd3c8a9625253744d9b67025b1856f"><gtr:id>8ecd3c8a9625253744d9b67025b1856f</gtr:id><gtr:otherNames>Awwad S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>5a2fd60059bbb0.70323277</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>545B8A97-1BED-4946-826E-8E695F6E6FD0</gtr:id><gtr:title>The Effects of Serum Amyloid P on Experimental Glaucoma Filtration Surgery</gtr:title><gtr:parentPublicationTitle>IOVS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/437acd0c9e7fda8265db3da16acfd42c"><gtr:id>437acd0c9e7fda8265db3da16acfd42c</gtr:id><gtr:otherNames>Georgoulas S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:outcomeId>547de3520d52e5.62248606</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C3BC8F18-4911-4489-A816-EE23C50EC773</gtr:id><gtr:title>Aulton's Pharmaceutics</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a42904897b54d74f04394c475036d53"><gtr:id>2a42904897b54d74f04394c475036d53</gtr:id><gtr:otherNames>Fadda H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:isbn>9780702042904</gtr:isbn><gtr:outcomeId>56c5e5e3df0bf7.18731441</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>533DFA45-0D63-489B-9655-BEF3EB6D3F16</gtr:id><gtr:title>Magnetic resonance imaging of the rabbit eye to determine the presence of bevacizumab (Avastin) tablet in the posterior sclera</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b26ff3e987388267f6cfd862ddb09f3"><gtr:id>8b26ff3e987388267f6cfd862ddb09f3</gtr:id><gtr:otherNames>Khaw PT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>tLTVgjj1qp9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0189A5BA-FF6A-47F5-B76C-BE93134B75BE</gtr:id><gtr:title>An ethylcellulose spacer is similar to mitomycin C in prolonging bleb survival in an experimental animal model</gtr:title><gtr:parentPublicationTitle>IOVS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e78f4e90605dcc535862ac16b713265"><gtr:id>8e78f4e90605dcc535862ac16b713265</gtr:id><gtr:otherNames>Lockwood A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>54649a89a52370.26163836</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A31F8144-0A82-4EF0-89F0-9C33CE8FA541</gtr:id><gtr:title>Determining the Concentration of the MMPi Ilomastat in Ocular Tissues Using HPLC</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e9288043632719a57098ebce34139229"><gtr:id>e9288043632719a57098ebce34139229</gtr:id><gtr:otherNames>Brocchini S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>sNtPLPr7jCn</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0DDBE254-78B3-4DE9-82BD-0DB859C5CF60</gtr:id><gtr:title>The effect of steroid and matrix metalloproteinase inhibitor on bleb survival in an experimental animal model</gtr:title><gtr:parentPublicationTitle>IOVS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e78f4e90605dcc535862ac16b713265"><gtr:id>8e78f4e90605dcc535862ac16b713265</gtr:id><gtr:otherNames>Lockwood A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>547deb4cf30144.78252051</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BE9AD2B4-64C3-475E-88A5-841D921A40FA</gtr:id><gtr:title>Hyaluronic acid based tablet for slow release of ilomastat in glaucoma filtration surgery</gtr:title><gtr:parentPublicationTitle>IOVS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1b73495a7ba62b35657629e45825682"><gtr:id>a1b73495a7ba62b35657629e45825682</gtr:id><gtr:otherNames>Mohamed Ahmed A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>547dec96e06f48.85721868</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>92B86D24-128D-4EDA-A853-48C202130EB5</gtr:id><gtr:title>A single application sustained release matrix metalloproteinase inhibitor at a low dose is superior to mitomycin C in prolonging bleb survival</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eb991ed27a85dc9d23ea0e3f5b577854"><gtr:id>eb991ed27a85dc9d23ea0e3f5b577854</gtr:id><gtr:otherNames>Lockwood, A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>DoXQRUYBoaR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A046A9E-16F8-4493-A37C-EAAFA3296972</gtr:id><gtr:title>Pharmaceutics</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d6abda6151a86ae5a97d9b1fa26e47c"><gtr:id>2d6abda6151a86ae5a97d9b1fa26e47c</gtr:id><gtr:otherNames>Fadda H, Khaw PT, Brocchini SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:isbn>9780702042904</gtr:isbn><gtr:outcomeId>JoNEEY7iaS8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>646A3823-CFDB-4B00-B307-26886B04E43B</gtr:id><gtr:title>The Effect Of A Water Soluble Matrix Metalloproteinase Inhibitor On Prolonging Bleb Survival In An Experimental Animal Model</gtr:title><gtr:parentPublicationTitle>IOVS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e78f4e90605dcc535862ac16b713265"><gtr:id>8e78f4e90605dcc535862ac16b713265</gtr:id><gtr:otherNames>Lockwood A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>547de90e70d002.53724863</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6D2536BA-C347-4A14-97F9-E696E5EDA80A</gtr:id><gtr:title>Molecular Dynamics Simulation of Ocular Tissue Tablets</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e2560bcf9e1dcd0c4473d6f4c7609862"><gtr:id>e2560bcf9e1dcd0c4473d6f4c7609862</gtr:id><gtr:otherNames>Ru Q</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>ttugm3MSVv5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A94E9899-2B8E-4788-81BA-21E5A50A6BE2</gtr:id><gtr:title>Cellulose Based Tablet For Sustained Release Of Ilomastat</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1b73495a7ba62b35657629e45825682"><gtr:id>a1b73495a7ba62b35657629e45825682</gtr:id><gtr:otherNames>Mohamed Ahmed A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>Gr7iy5YG1T3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A06F06E-E1E3-4CC5-9212-B0587A37C206</gtr:id><gtr:title>The effect of a water-soluble matrix metalloproteinase inhibitor on prolonging bleb survival in an experimental animal model</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e78f4e90605dcc535862ac16b713265"><gtr:id>8e78f4e90605dcc535862ac16b713265</gtr:id><gtr:otherNames>Lockwood A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>LRt3sk3pa4x</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0DD5FFBC-B6C8-490A-ABDA-DFE0F10C08BB</gtr:id><gtr:title>ISGS Textbook of Glaucoma Surgery</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7f205256d58e116c0782f573209d784b"><gtr:id>7f205256d58e116c0782f573209d784b</gtr:id><gtr:otherNames>Khaw P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:isbn>9789351522065</gtr:isbn><gtr:outcomeId>547da837e97a05.53907820</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>236932FB-0165-4079-9E17-0F619296D211</gtr:id><gtr:title>Surface Analysis of Ilomastat Tissue Tablet Following Incubation in Simulated Aqueous Fluid</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d05b5a9775b711c5d24459949a4aed77"><gtr:id>d05b5a9775b711c5d24459949a4aed77</gtr:id><gtr:otherNames>Ellis J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>JFPD1EJE5F7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8BBB6E1D-D185-40BA-8D50-C3ED01F9BBDB</gtr:id><gtr:title>Repair To Regeneration: Converting Laboratory Discovery to Clinical Advance Translational Research in Glaucoma</gtr:title><gtr:parentPublicationTitle>Review of Optometry/Optometic Glaucoma</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b26ff3e987388267f6cfd862ddb09f3"><gtr:id>8b26ff3e987388267f6cfd862ddb09f3</gtr:id><gtr:otherNames>Khaw PT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>538f33903b1068.26988551</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F7E9E84E-0821-4BC8-834E-F9AFE1A598D9</gtr:id><gtr:title>In vitro Modeling of Ocular Tissue Tablets</gtr:title><gtr:parentPublicationTitle>IOVS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e2560bcf9e1dcd0c4473d6f4c7609862"><gtr:id>e2560bcf9e1dcd0c4473d6f4c7609862</gtr:id><gtr:otherNames>Ru Q</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:outcomeId>547de2e752b157.11364473</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5421F83E-C5BF-4122-BDDE-3EBB954FDCA4</gtr:id><gtr:title>Enhanced trabeculectomy: the Moorfields Safer Surgery System.</gtr:title><gtr:parentPublicationTitle>Developments in ophthalmology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b26ff3e987388267f6cfd862ddb09f3"><gtr:id>8b26ff3e987388267f6cfd862ddb09f3</gtr:id><gtr:otherNames>Khaw PT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0250-3751</gtr:issn><gtr:outcomeId>pm_12768_28_22517170</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1E42AC10-3AF6-49E3-B4CE-76E86C0CB0B5</gtr:id><gtr:title>Ocular Disease</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/437acd0c9e7fda8265db3da16acfd42c"><gtr:id>437acd0c9e7fda8265db3da16acfd42c</gtr:id><gtr:otherNames>Georgoulas S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:isbn>9780702029837</gtr:isbn><gtr:outcomeId>56c5e7321fbbd7.17239629</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1BAE3823-0945-4618-BBD1-8DB31CECE6A0</gtr:id><gtr:title>The impact of wound healing on glaucoma therapy</gtr:title><gtr:parentPublicationTitle>Glaucoma Today</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e78f4e90605dcc535862ac16b713265"><gtr:id>8e78f4e90605dcc535862ac16b713265</gtr:id><gtr:otherNames>Lockwood A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>547db4b51191b3.30395185</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>50C64AE5-5416-47AF-952B-A4887237CCEA</gtr:id><gtr:title>Understanding Changes in the Solid Phase Properties of Tissue Tablets on Exposure to Aqueous Media</gtr:title><gtr:parentPublicationTitle>IOVS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3c68b694e7f92769b8fa9fab4da1789d"><gtr:id>3c68b694e7f92769b8fa9fab4da1789d</gtr:id><gtr:otherNames>Fadda HM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>547de46ada8c26.54417530</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9BF91883-832B-4AA2-A75B-DC8F1D6E732C</gtr:id><gtr:title>Cellulose Based Tablet For Sustained Release Of Ilomastat</gtr:title><gtr:parentPublicationTitle>IOVS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1b73495a7ba62b35657629e45825682"><gtr:id>a1b73495a7ba62b35657629e45825682</gtr:id><gtr:otherNames>Mohamed Ahmed A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>547de93eab3247.16784003</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9B93EAA3-D115-4239-826D-934356E4CA69</gtr:id><gtr:title>Ophthalmology</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b26ff3e987388267f6cfd862ddb09f3"><gtr:id>8b26ff3e987388267f6cfd862ddb09f3</gtr:id><gtr:otherNames>Khaw PT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:isbn>9781455739844</gtr:isbn><gtr:outcomeId>547db163e9b9c0.30796027</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0A35DB0B-A3A9-4F2B-8E33-DCF0FEFAA617</gtr:id><gtr:title>New developments in the pharmacological modulation of wound healing after glaucoma filtration surgery.</gtr:title><gtr:parentPublicationTitle>Current opinion in pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e78f4e90605dcc535862ac16b713265"><gtr:id>8e78f4e90605dcc535862ac16b713265</gtr:id><gtr:otherNames>Lockwood A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1471-4892</gtr:issn><gtr:outcomeId>543e7bc31c9183.50625260</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E4147C85-11AC-4A3B-A37B-B51EDB4A060A</gtr:id><gtr:title>Molecular dynamic simulations of ocular tablet dissolution.</gtr:title><gtr:parentPublicationTitle>Journal of chemical information and modeling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e2560bcf9e1dcd0c4473d6f4c7609862"><gtr:id>e2560bcf9e1dcd0c4473d6f4c7609862</gtr:id><gtr:otherNames>Ru Q</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1549-9596</gtr:issn><gtr:outcomeId>543e76b8965d64.27392261</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3330EADE-4C3F-40AA-8A87-B573CA62C70B</gtr:id><gtr:title>The effect of MMP inhibitor GM6001 on early fibroblast-mediated collagen matrix contraction is correlated to a decrease in cell protrusive activity.</gtr:title><gtr:parentPublicationTitle>European journal of cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b3f6f15e5d4e5acf05d2d732064c30f"><gtr:id>9b3f6f15e5d4e5acf05d2d732064c30f</gtr:id><gtr:otherNames>Martin-Martin B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0171-9335</gtr:issn><gtr:outcomeId>pm_12768_28_21040999</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A3D089C3-E015-4670-B41C-68006B5B2EDD</gtr:id><gtr:title>Understanding changes in the solid phase properties of tissue tablets on exposure to aqueous media</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a42904897b54d74f04394c475036d53"><gtr:id>2a42904897b54d74f04394c475036d53</gtr:id><gtr:otherNames>Fadda H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>TbtcFmzem6e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>00B0352A-BA6C-466D-A233-77D6F28414E6</gtr:id><gtr:title>A Vision for Horizon 2020 - A European Strategic Roadmap for Vision Research and Ophthalmology</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7f205256d58e116c0782f573209d784b"><gtr:id>7f205256d58e116c0782f573209d784b</gtr:id><gtr:otherNames>Khaw P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>Wf8VjPswfcF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D5D3E9F-7127-43F4-9152-57949F9002EE</gtr:id><gtr:title>Ocular Disease: Mechanisms and Management</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/437acd0c9e7fda8265db3da16acfd42c"><gtr:id>437acd0c9e7fda8265db3da16acfd42c</gtr:id><gtr:otherNames>Georgoulas S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:isbn>9780702029837</gtr:isbn><gtr:outcomeId>547daa64d15474.96079925</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7C35C85A-B626-4759-AD70-FF84AFA36B80</gtr:id><gtr:title>The Potential of Lenalidomide to Control Scarring in Experimental Models of Glaucoma Filtration Surgery</gtr:title><gtr:parentPublicationTitle>IOVS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/248670cd9e85af9086b637bb531ae19e"><gtr:id>248670cd9e85af9086b637bb531ae19e</gtr:id><gtr:otherNames>Khalili A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>547de6daedaf03.76896551</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B5AF1ACC-7B7F-4A6A-A8EC-5E55F5DBBB8B</gtr:id><gtr:title>Characterisation of ilomastat for prolonged ocular drug release.</gtr:title><gtr:parentPublicationTitle>AAPS PharmSciTech</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cd84a5964e8adc4b64d8b2e8d5630cc7"><gtr:id>cd84a5964e8adc4b64d8b2e8d5630cc7</gtr:id><gtr:otherNames>Parkinson G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1530-9932</gtr:issn><gtr:outcomeId>h94UKf4AzmL</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9F8AF753-F8BA-45CC-A321-73C94C9DE41C</gtr:id><gtr:title>Proteins in solid dosage form (implantable tablets) for ocular delivery</gtr:title><gtr:parentPublicationTitle>IOVS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d4d9e563ee09e60734401c706a315277"><gtr:id>d4d9e563ee09e60734401c706a315277</gtr:id><gtr:otherNames>Khalil A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>547dec2f060f95.17412823</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9B248190-71C8-4B6E-AECE-3FFE3A326E17</gtr:id><gtr:title>The effect of gamma irradiation on the physicochemical properties of a matrix metalloproteinase inhibitor, ilomastat: a multi-supplier consistency study</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d5ec7c39a6c847edf801731d4edd0c65"><gtr:id>d5ec7c39a6c847edf801731d4edd0c65</gtr:id><gtr:otherNames>Vetter A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>ADSdypUMnJ5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>71974059-1EA3-45CC-9B28-E04367AC6BCA</gtr:id><gtr:title>Rac1 inhibition prevents tissue contraction and MMP mediated matrix remodeling in the conjunctiva.</gtr:title><gtr:parentPublicationTitle>Investigative ophthalmology &amp; visual science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b847abee8ff432e1aa86afb9f5a4dec5"><gtr:id>b847abee8ff432e1aa86afb9f5a4dec5</gtr:id><gtr:otherNames>Tovell VE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0146-0404</gtr:issn><gtr:outcomeId>doi_12768_vs_11_8577</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>67BE6BCC-960F-4BD0-9CB1-96C3A9EFBA49</gtr:id><gtr:title>Cataract Surgery in the Glaucoma Patient</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c2d037208d6e04fb595ec148fd85d9c"><gtr:id>2c2d037208d6e04fb595ec148fd85d9c</gtr:id><gtr:otherNames>Dhingra S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:isbn>978-0-387-094076)	</gtr:isbn><gtr:outcomeId>547db1fae7a783.69829756</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>59747774-C67E-4270-A073-F9925C8AFF42</gtr:id><gtr:title>Surface Analysis of Ilomastat Tissue Tablet Following Incubation in Simulated Aqueous Fluid</gtr:title><gtr:parentPublicationTitle>IOVS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/310ca6b1998cc00d6fbb83fd221ceee6"><gtr:id>310ca6b1998cc00d6fbb83fd221ceee6</gtr:id><gtr:otherNames>Ellis JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>547de65430e928.71610943</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8BBA6A58-BF5F-4150-B5A0-7A1B94841970</gtr:id><gtr:title>Quality use of antifibrotics in trabeculectomy</gtr:title><gtr:parentPublicationTitle>Glaucoma Today</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b26ff3e987388267f6cfd862ddb09f3"><gtr:id>8b26ff3e987388267f6cfd862ddb09f3</gtr:id><gtr:otherNames>Khaw PT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>547db598d38998.17221507</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5513442D-B421-4E16-8803-BA384301EFD3</gtr:id><gtr:title>The Effect Of Scleral Flap Shape And Size On Aqueous Flow And Pressure Following Trabeculectomy: Implications From Mathematical And Physical Modelling</gtr:title><gtr:parentPublicationTitle>IOVS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c2d037208d6e04fb595ec148fd85d9c"><gtr:id>2c2d037208d6e04fb595ec148fd85d9c</gtr:id><gtr:otherNames>Dhingra S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>547de8ab5b8b61.68737881</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>15FD3833-7A9B-46E4-A157-E9FE46474BA1</gtr:id><gtr:title>A Single Application Sustained Release Matrix Metalloproteinase Inhibitor At A Low Dose Is Superior To Mitomycin C In Prolonging Bleb Survival</gtr:title><gtr:parentPublicationTitle>IOVS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e78f4e90605dcc535862ac16b713265"><gtr:id>8e78f4e90605dcc535862ac16b713265</gtr:id><gtr:otherNames>Lockwood A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>547de7a83444d7.06438884</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6CAE6DB2-8DE6-41E5-AC67-963285B63DC7</gtr:id><gtr:title>Prolonged Local Ocular Delivery of an Antibody</gtr:title><gtr:parentPublicationTitle>IOVS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/248670cd9e85af9086b637bb531ae19e"><gtr:id>248670cd9e85af9086b637bb531ae19e</gtr:id><gtr:otherNames>Khalili A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:outcomeId>547de31d5a8f67.88743418</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F846B285-EC75-466B-AA45-ED89D97BEC87</gtr:id><gtr:title>An Ilomastat-CD Eye Drop Formulation to Treat Ocular Scarring.</gtr:title><gtr:parentPublicationTitle>Investigative ophthalmology &amp; visual science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f667712487e80557c532d0d17a670f73"><gtr:id>f667712487e80557c532d0d17a670f73</gtr:id><gtr:otherNames>Mohamed-Ahmed AHA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0146-0404</gtr:issn><gtr:outcomeId>5a2fd599ab4829.08006234</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CD48D367-C903-4097-9920-7031986DD911</gtr:id><gtr:title>Glaucoma Now</gtr:title><gtr:parentPublicationTitle>Minimising scarring after glaucoma surgery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/056d842d169854930e5220ad3da15f14"><gtr:id>056d842d169854930e5220ad3da15f14</gtr:id><gtr:otherNames>Lee R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56c5df77b9e7a6.05866431</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A6B85E41-DD2B-416F-9EE8-C8D958F31630</gtr:id><gtr:title>Magnetic Resonance Imaging of the Rabbit Eye to Determine the Presence of Bevacizumab (Avastin) Tablet in the Posterior Sclera</gtr:title><gtr:parentPublicationTitle>IOVS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b26ff3e987388267f6cfd862ddb09f3"><gtr:id>8b26ff3e987388267f6cfd862ddb09f3</gtr:id><gtr:otherNames>Khaw PT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>547de7128dfa54.49475031</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A549B298-1522-4DDA-86A0-DD3A7F6394F3</gtr:id><gtr:title>Pearls of Glaucoma Management</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c86ee5a164cbd848cea35d2dbc9deee8"><gtr:id>c86ee5a164cbd848cea35d2dbc9deee8</gtr:id><gtr:otherNames>Ressiniotis T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:isbn>978-3-540-68238-7</gtr:isbn><gtr:outcomeId>56c5e7987b1399.76062542</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0801650</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>A9061818-9B1E-495A-9617-7C77200827C2</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Eye</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>